Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could ketamine be the key to easing sickle cell pain in kids?

NCT ID NCT07369024

Recruiting now Symptom relief Sponsor: Mohsen Saidinejad Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a low dose of ketamine, given alongside standard pain medicine, can better control severe pain from sickle cell disease in children and young adults aged 5 to 20. Participants will receive either ketamine or a placebo infusion, and researchers will measure how much opioid pain medicine they need and how quickly their pain improves. The goal is to find a safer, more effective way to manage sickle cell pain crises.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ketamine
What this could lead to
If it works, this could offer a safer, more effective way to manage severe sickle cell pain in young people, potentially reducing reliance on opioids.
What could go wrong
This is a Phase 2 trial with only 120 participants, so results are preliminary. Ketamine may not provide additional pain relief and could cause side effects like dizziness or hallucinations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KETAMINE INFUSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agnosia sickle cell disease Vaso-Occlusive Crises

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KETAMINE INFUSION PAIN MANAGEMENT SICKLE CELL DISEASE VASO-OCCLUSIVE CRISES VASO-OCCLUSIVE PAIN EPISODE IN SICKLE CELL DISEASE

Contacts and locations

Locations

  • Harbor UCLA Medical Center

    RECRUITING

    Torrance, California, 90509, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.